GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (NAS:LPTX) » Definitions » E10

Leap Therapeutics (Leap Therapeutics) E10 : $-16.34 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Leap Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Leap Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-16.34 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-28), Leap Therapeutics's current stock price is $3.25. Leap Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-16.34. Leap Therapeutics's Shiller PE Ratio of today is .


Leap Therapeutics E10 Historical Data

The historical data trend for Leap Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics E10 Chart

Leap Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -16.78 -16.34

Leap Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.78 -17.23 -17.31 -16.69 -16.34

Competitive Comparison of Leap Therapeutics's E10

For the Biotechnology subindustry, Leap Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Leap Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's Shiller PE Ratio falls into.



Leap Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Leap Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.2/129.4194*129.4194
=-0.200

Current CPI (Dec. 2023) = 129.4194.

Leap Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -2.103 99.695 -2.730
201406 -2.726 100.560 -3.508
201409 -7.000 100.428 -9.021
201412 -4.666 99.070 -6.095
201503 -3.800 99.621 -4.937
201506 -3.600 100.684 -4.627
201509 -3.200 100.392 -4.125
201512 4.312 99.792 5.592
201603 -3.013 100.470 -3.881
201606 -4.377 101.688 -5.571
201609 -4.260 101.861 -5.413
201612 -3.355 101.863 -4.263
201703 -13.900 102.862 -17.489
201706 -7.400 103.349 -9.267
201709 -7.300 104.136 -9.072
201712 -6.500 104.011 -8.088
201803 -8.500 105.290 -10.448
201806 -5.000 106.317 -6.086
201809 -5.500 106.507 -6.683
201812 -3.500 105.998 -4.273
201903 -4.700 107.251 -5.671
201906 -3.700 108.070 -4.431
201909 -3.300 108.329 -3.942
201912 -3.300 108.420 -3.939
202003 -5.500 108.902 -6.536
202006 -1.200 108.767 -1.428
202009 -0.900 109.815 -1.061
202012 -0.900 109.897 -1.060
202103 -1.200 111.754 -1.390
202106 -1.200 114.631 -1.355
202109 -1.400 115.734 -1.566
202112 -1.000 117.630 -1.100
202203 -0.900 121.301 -0.960
202206 -1.500 125.017 -1.553
202209 -1.330 125.227 -1.375
202212 -1.100 125.222 -1.137
202303 -3.200 127.348 -3.252
202306 -0.910 128.729 -0.915
202309 -0.510 129.860 -0.508
202312 -0.200 129.419 -0.200

Add all the adjusted EPS together and divide 10 will get our e10.


Leap Therapeutics  (NAS:LPTX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Leap Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Leap Therapeutics (Leap Therapeutics) Business Description

Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Executives
Jason Baum officer: Chief Scientific Officer LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Patricia A. Martin director 316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260
Christian M Richard director 100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110
Richard Schilsky director LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Beigene, Ltd. 10 percent owner C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christine Granfield officer: VP, Head of Reg Affairs/Qual C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Mark O'mahony officer: Chief Manufacturing Officer C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Cynthia Sirard officer: Chief Medical Officer C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher Mirabelli director, 10 percent owner, officer: CEO,Pres,Chairman of the Board 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Augustine Lawlor 10 percent owner, officer: Chief Operating Officer 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Douglas E Onsi 10 percent owner, officer: CFO,Gen Counsel,Treas, Sec. C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Healthcare Ventures Ix, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142

Leap Therapeutics (Leap Therapeutics) Headlines

From GuruFocus

Leap Therapeutics Announces Reverse Stock Split

By PRNewswire PRNewswire 06-20-2023

Leap Therapeutics Acquires Flame Biosciences

By PRNewswire PRNewswire 01-17-2023